Dupixent Lawsuit Dupixent lawsuits are being investigated for patients who developed rare blood cancers such as cutaneous T-cell lymphoma (CTCL) after receiving injections, alleging that Sanofi and Regeneron failed to warn about the potential risks of immune suppression and delayed cancer diagnosis.
Tabletop Fire Pit Lawsuit Individuals who suffered severe burns, or families who lost a loved one in a tabletop fire pit explosion, may be eligible for financial compensation through a fire pit injury lawsuit.
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
FDA Approves Tepezza For Wide Use To Treat Thyroid Eye Disease (TED), Amid Reports of Irreversible Hearing Damage The updated Tepezza label could significantly expand use of the thyroid eye disease treatment, even as lawsuits are being pursued over failure to warn about the hearing damage risks April 17, 2023 Irvin Jackson Add Your Comments As Horizon Therapeutics faces a growing number of Tepezza lawsuits, alleging that users were not adequately warned about the risk of irreversible hearing damage, the drug maker is pushing for wider use of the infusion treatment for thyroid eye disease (TED). In a press release issued on April 14, the Tepezza manufacturer announced that the U.S. Food and Drug Administration (FDA) has granted approval for Tepezza to be used by a wider number of individuals. Tepezza (teprotumumab-trbw) is a new-generation biologic treatment introduced in January 2020, as the first medication approved for thyroid eye disease, or bulging eyes, which is caused by hyperthyroidism and linked to Graves’ disease, resulting in inflammation of eye muscles, eyelids, tear glands and fatty tissues behind the eye. Originally, the FDA approved Tepezza for treatment of Thyroid Eye Disease among individuals who had the disease for nine months or less. The updated labeling approves Tepezza for the treatment of the disease for all patients, regardless of how long they have been experiencing the condition. Tepezza Failure to Warn Lawsuits The expanded FDA Tepezza approval comes as the drug maker already faces criticism for over-promoting the thyroid eye disease treatment, and withholding information from users and the medical community about the risk of long-term hearing loss or tinnitus. Tepezza Lawsuits Did You or a Loved One Receive a Tepezza Injection? Side effects of Tepezza may cause permanent hearing problems. Lawsuits are being pursued over the drug maker’s failure to warn about the risk. Find out if qualify for a settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Tepezza Lawsuits Did You or a Loved One Receive a Tepezza Injection? Side effects of Tepezza may cause permanent hearing problems. Lawsuits are being pursued over the drug maker’s failure to warn about the risk. Find out if qualify for a settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Although Tepezza was originally intended as a niche treatment, with only a limited market, during the second year the drug was on the market in the United States sales doubled to $1.66 billion, and critics have expressed concern that Tepezza was aggressively marketed without adequately disclosing all of the potential risks. Hundreds of former users are now coming forward to report that they experienced various forms of hearing problems from Tepezza, including persistent ringing in the ears known as tinnitus, and complete hearing loss. In many cases, the problems persist long after the thyroid eye disease treatments, leaving users with irreversible hearing damage. According to allegations raised in recently filed product liability lawsuits over Tepezza, plaintiffs indicate that they may have avoided irreversible hearing damage if the drug maker had warned users and doctors about the importance of reporting symptoms of hearing loss, and conducting audiological monitoring during the treatments. Updated Tepezza Label The expanded indications now approved on the Tepezza label follow the results of a clinical trial, which showed the drug to be effective in treating patients who had thyroid eye disease for between two and 10 years. The results are preliminary, however, and have not yet been published in a peer-reviewed medical journal. The FDA’s label update specifies that Tepezza is now approved for the treatment of thyroid eye disease regardless of how long the patient has had the disease or the number of adverse events the patient has experienced from the condition. The label update is likely to expand the willingness of doctors to prescribe the drug to their patients and gives Horizon the ability to legally market the drug to virtually anyone with thyroid eye disease. April 2023 Tepezza Hearing Loss Lawsuit Update Given common questions of fact and law raised in Tepezza hearing loss lawsuits filed throughout the federal court system, the U.S. Judicial Panel on Multidistrict Litigation (JPML) has been asked to centralize the claims before one judge for coordinated discovery and pretrial proceedings, as part of a Tepezza MDL, or multidistrict litigation. Each of the lawsuits claim Horizon Therapeutics, the manufacturer, should have been aware of the link between Tepezza and hearing loss before it was ever submitted to U.S. regulators for review, since the drug impacts the insulin-like growth factor I, which is known to play a central role in hearing and low levels have been shown to correlate with human syndromes associated with hearing loss. However, plaintiffs say the drug maker failed to adequately test Tepezza, ignored pose marketing reports that clearly indicated users were experiencing hearing loss, and provided false and misleading information about the safety risks with Tepezza, according to the complaints. In complex pharmaceutical litigation, where large numbers of claims are brought by users of the same medication or medical product, each experiencing the same or similar injuries, it is common for the U.S. JPML to centralize the litigation to reduce duplicative discovery into common issues that will arise in all claims, avoid conflicting pretrial rulings and to serve the convenience of certain witnesses and parties who will be required to testify in each of the lawsuits. As Tepezza injury lawyers continue to review and file claims for individuals who experienced hearing problems after receiving the thyroid eye disease treatment, it is ultimately expected that several hundred claims will be brought throughout the federal court system. If an MDL is established, each individual claim may later be remanded back to the U.S. District Court where it was originally filed for trial, if the parties fail to negotiate Tepezza settlements or another resolution for the claims. The JPML has indicated it will hear oral arguments on Tepezza lawsuit consolidation at a hearing in late May. Written by: Irvin Jackson Senior Legal Journalist & Contributing Editor Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends. Tags: Hearing Damage, Hearing Loss, Horizon Therapeutics, Tepezza, Thyroid Eye Disease More Tepezza Lawsuit Stories Tepezza Hearing Loss Trial Date Pushed Back to Aug. 2026 August 27, 2025 Tepezza Lawsuit Claims Thyroid Eye Disease Drug Caused Hearing Loss, Tinnitus August 13, 2025 First Tepezza Hearing Loss Lawsuit Set To Go Before Jury in June 2026 July 21, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Wayfair Fire Pit Lawsuit Links Flame Jetting Explosion to Defective Design (Posted: yesterday) In March 2026, a jury is scheduled to hear a Wayfair fire pit lawsuit from a woman who suffered burns to nearly half her body. MORE ABOUT: TABLETOP FIRE PIT LAWSUITAmazon Tabletop Fire Pit Lawsuit Alleges ‘Flame-Jetting’ Caused Third Degree Burns (08/29/2025)Tabletop Fire Pit Burn Victims Share Stories of Explosions and Devastating Injuries (08/21/2025)Colsen Fire Pit Lawsuit Involving Severe Burn Injuries Suffered by a Child Set for Trial Next Year (08/14/2025) Dupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks (Posted: 2 days ago) Dupixent lawsuits are now being investigated after studies and FDA reports link Dupixent (dupilumab) to cutaneous T-cell lymphoma (CTCL). MORE ABOUT: DUPIXENT LAWSUITDupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks (08/26/2025) Depo-Provera Meningioma Side Effects Significantly Increased Among Women Over 31: Study (Posted: 3 days ago) A new study appears to further confirm and quantify the risks of Depo-Provera meningioma side effects, potentially providing further evidence for growing litigation. MORE ABOUT: DEPO-PROVERA LAWSUITPfizer Seeks Dismissal of Depo-Provera Failure-To-Warn Lawsuits Over Meningioma Risks (09/02/2025)Nearly 1,000 Depo-Provera Meningioma Lawsuits Filed, With Another 9,500 Under Investigation (08/25/2025)Experts Weigh In On Depo-Provera Brain Tumor Risks, As Lawsuits Continue to Mount (08/20/2025)
Wayfair Fire Pit Lawsuit Links Flame Jetting Explosion to Defective Design (Posted: yesterday) In March 2026, a jury is scheduled to hear a Wayfair fire pit lawsuit from a woman who suffered burns to nearly half her body. MORE ABOUT: TABLETOP FIRE PIT LAWSUITAmazon Tabletop Fire Pit Lawsuit Alleges ‘Flame-Jetting’ Caused Third Degree Burns (08/29/2025)Tabletop Fire Pit Burn Victims Share Stories of Explosions and Devastating Injuries (08/21/2025)Colsen Fire Pit Lawsuit Involving Severe Burn Injuries Suffered by a Child Set for Trial Next Year (08/14/2025)
Dupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks (Posted: 2 days ago) Dupixent lawsuits are now being investigated after studies and FDA reports link Dupixent (dupilumab) to cutaneous T-cell lymphoma (CTCL). MORE ABOUT: DUPIXENT LAWSUITDupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks (08/26/2025)
Depo-Provera Meningioma Side Effects Significantly Increased Among Women Over 31: Study (Posted: 3 days ago) A new study appears to further confirm and quantify the risks of Depo-Provera meningioma side effects, potentially providing further evidence for growing litigation. MORE ABOUT: DEPO-PROVERA LAWSUITPfizer Seeks Dismissal of Depo-Provera Failure-To-Warn Lawsuits Over Meningioma Risks (09/02/2025)Nearly 1,000 Depo-Provera Meningioma Lawsuits Filed, With Another 9,500 Under Investigation (08/25/2025)Experts Weigh In On Depo-Provera Brain Tumor Risks, As Lawsuits Continue to Mount (08/20/2025)